Guidance has been published in the UK regarding a new European variations regulation that comes into effect on 1 January 2010.
Guidance has been published in the UK regarding a new European variations regulation that comes into effect on 1 January 2010. After consultation, UK health ministers have agreed that the new rules will be adopted for all variations to marketing authorizations, including those held only in the UK. Additionally, an amending fees regulation will be implemented in the UK to establish fees for the new types of work specified in the Commission regulation. The information has been published on the UK's Medicines and Healthcare products Regulatory Agency (MHRA) website.
, which will replace Regulations 1084/2003/EC and 1085/2003/EC, concerns variations to the terms of marketing authorizations that have been granted by the Commission in Centralized Procedures and by the National Licensing Authorities in Mutual Recognition, Decentralized or other 'harmonizing' European Procedures.
According to the MHRA, the Commission also intends to extend the scope of the regulation to include variations to 'purely National' marketing authorizations. This will require further legislative changes and will probably not be implemented until 2011. UK health ministers, however, have agreed that the rules within the new regulation will be adopted for all variations to the terms of marketing authorizations, including those granted in 'purely National' procedures.
The UK agency has also introduced, as of 1 January 2010, new fee categories to cover grouped and bulk-group applications for multiple changes submitted as part of the same variation application and applications where the UK is the 'Reference Authority' in a European worksharing procedure.
Further details can be found in the MHRA's National MA Variations Guidance.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.